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A treatment containing a live food-grade organism, Lactococcus lactis DPC3147, was compared
with conventional antibiotic therapy for its potential to treat bovine chronic subclinical or
clinical mastitis in two separate field trials. Effects on disease symptoms and bacteriology were
monitored in response to infusion with the culture in each trial. In the first trial, the live culture
treatment was compared with an intramammary antibiotic (n=11 quarters for each treatment).
Results from this small trial demonstrated that the live culture had potential to be as effective at
eliminating chronic subclinical infections as an antibiotic treatment. By day 12, 7 of the 11
quarters treated with the live culture were pathogen-free compared with 5 of the 11 antibiotic-
treated infected quarters. Somatic cell counts (SCC) remained relatively unchanged regardless
of treatment: average log SCC pre- and post-treatment in the lactococci-treated group were
6.33±0.41 (day 0) and 6.27±0.43 cells/ml (day 12) and average log SCC pre- and post-
treatment in the antibiotic-treated group were 6.34±0.37 and 6.22±0.46 cells/ml on day 0 and
on day 12, respectively. In the second trial, the live culture was compared with an
intramammary antibiotic for the treatment of naturally occurring clinical mastitis cases (n=25
quarters for each treatment). Following a 14-d experimental period, similar bacteriological
responses were observed in 7 out of 25 live culture treated quarters and 9 out of 25 antibiotic-
treated quarters. Additionally, 15 of 25 cases treated with the culture and 18 of 25 cases treated
with the antibiotic did not exhibit clinical signs of the disease following treatment. The results of
these trials suggest that live culture treatment with Lc. lactis DPC3147 may be as efficacious as
common antibiotic treatments in some instances.
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Mastitis is considered the most persistent disease in dairy
cows and is of great economic importance as it is as-
sociated with decreased milk production, expensive treat-
ment costs, extra labour and an increased rate of culling
(Klaas et al. 2004). Treatment of the disease accounts for
the most common cause of antibiotic use in dairy cows,
where it can lead to antibiotic residues in milk with con-
comitant economic losses due to discarding milk during
and post treatment (Kaneene & Miller, 1992; Costello,
2004). In addition, some studies suggest that antibiotics
may be relatively ineffective for the treatment of pathogens
like Staphylococcus aureus, which can internalize in
eukaryotic host cells, evading the immune system
(Barkema et al. 2006). An effective, non-antibiotic mastitis
treatment could reduce costs associated with antibiotic
therapy and would also relieve some of the pressures
facing the agricultural and veterinary sectors to limit the
use of antibiotics. Several alternative approaches have
therefore been used in the treatment of mastitis, including
milking the infected quarter several times a day (Roberson
et al. 2004), hydrotherapy, intramammary infusions of
glucose solutions (Reinhold et al. 1986) and the use of
lysostaphin (Oldham & Daley, 1991) and nisin (Cao et al.
2007; Wu et al. 2007). Other remedies have included
the use of casein hydrolysates (Silanikove et al. 2005),
hot and cold packing, ultrasonic therapy, topically applied
liniments (Knight et al. 2000), drugs such as the milk*For correspondence; e-mail paul.ross@teagasc.ie
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ejection hormone oxytocin (Guterbock et al. 1993), anti-
histamines, steroids, non-steroidal anti-inflammatories and
homoeopathic preparations (Varshney & Naresh, 2004).
Furthermore, the intramammary treatment of subclinical
mastitis with Lactobacillus species through competitive
elimination has been studied by Greene et al. (1991).
In the animal trials reported in this paper, a novel non-
antibiotic treatment, consisting of a live culture suspension
of Lactococcus lactis DPC3147, was examined for its
ability to treat naturally occurring mastitis. Lc. lactis
DPC3147 belongs to a family of bacteria known collec-
tively as the lactic acid bacteria. These organisms are
widely used in the dairy industry as starters for fermen-
tative processes and, as such, are food grade. Lc. lactis
DPC3147 produces the bacteriocin lacticin 3147, a two-
component lantibiotic (Ryan et al. 1999b), which inhibits
a broad spectrum of Gram-positive bacteria including
mastitis-causing bacteria such as streptococci and staphy-
lococci (Ryan et al. 1998). Indeed, it was previously
shown that the bacteriocin itself can reduce the incidence
of mastitis after experimental challenge in non-lactating
dairy cows when incorporated in a Teat Seal preparation
(Ryan et al. 1999a). More recently, a whey containing
lacticin 3147 formulation in a bismuth-based teat seal was
effective in reducing bacterial recoveries from teats delib-
erately infected with Staphylococcus aureus in lactating
dairy cows (Crispie et al. 2005).
In the present study, a live culture of Lc. lactis was
assessed for efficacy in the treatment of bovine mastitis.
Naturally infected animals were used in two trials, limiting
case numbers and study size to small, preliminary trials of
a size comparable to that reported previously (Greene et
al. 1991). In Trial 1, the live culture treatment was used in
subclinical cases caused mostly by Staph. aureus, whereas
in Trial 2, the efficacy of infusing a live culture of Lc. lactis
DPC3147 for the treatment of acute clinical mastitis in
lactating dairy cows was assessed.
Materials and Methods
Selection of animals and clinical assessment
Cows for both trials were selected from four adjacent herds
mainly consisting of Holstein-Friesian cows as well as
small numbers of New Zealand Friesians, Norwegian
Reds, Normandes and Montbelliards. Following selection
of suitable quarters, Trial 1 was undertaken over a 2-week
period in July 2003. Detection of naturally occurring
clinical cases of mastitis and enrolment of quarters in Trial
2 was undertaken over a period of 8 months beginning
in January 2005. All cows enrolled in the study were
routinely milked twice a day where pre-milking udder
preparation consisted of washing with water, forestripping
and drying teats with service paper towels. Following
milking, teats were sprayed with Deosan Summer Teatcare
Plus (RTU, Diversey Lever) a ready-to-use teat skin dis-
infectant containing chlorhexidine. At the end of their
lactation period, the teats of all cows were infused with
long-acting antibiotics (dry cow treatment).
In Trial 1, chronic subclinical mastitis cases were used
to evaluate the treatment. Selection of animals was made
using a combination of SCC and bacteriological data from
quarter milk samples. Composite milk of individual cows
was also sampled at monthly intervals throughout the lac-
tation. SCC in the milk samples was determined using a
Somacount 300 (Bentley Instruments Incorporated, USA).
Similarly to previous studies (Berry & Meaney, 2006;
Kivaria et al. 2007; Sandgren et al. 2008) cases were de-
fined as ‘chronic subclinical ’ when the SCC was elevated
(>3r105 cells/ml) in at least two samples and a pathogen
was present or when the SCC was elevated (>3r105 cells/
ml) in at least three samples and no pathogen was present.
There was no swelling of the udder or visible abnormali-
ties in the milk of chronic subclinically infected quarters.
Twenty-two chronic subclinical infections were selected in
12 cows in Trial 1. Eleven cases were infused with culture
and 11 cases were infused with an intramammary anti-
biotic.
In Trial 2, newly acquired clinical cases of mastitis were
detected by trained dairy personnel during the process of
forestripping. Quarters were classified as having clinical
mastitis when an udder quarter was inflamed and visible
abnormalities such as clots were present in the milk.
Clinical cases were subsequently assessed by a member of
the study team as to the severity of the individual case and
classified as either mild or severe based on milk and udder
appearance and rectal temperature. If the clots in the
foremilk were small to medium in size and the milk and
udder showed slight abnormalities, such as ‘watery’ con-
sistency and slight swelling and tenderness of the udder
quarter, the case was enrolled as mild. Mild cases had
rectal temperatures ranging from 38.5 8C to 39.5 8C. In
contrast, if clots were large and the foremilk appeared
abnormal in character, the disease was classified as severe.
In severe cases the udder quarter was swollen, hot and
painful to the touch and rectal body temperatures were
39.5 8C or higher. Overall in Trial 2, 50 cases of clinical
mastitis were identified in 48 cows and randomly assigned
at the time of detection to either culture or antibiotic
treatment respectively. Two cows showing clinical mastitis
in two different quarters at different time points were as-
signed once to culture treatment and once to antibiotic
treatment. Udder condition, rectal temperatures and SCC
were assessed throughout the trial by trained farm staff and
veterinary personnel.
Preparation of live culture treatments
The live culture was prepared as follows: Lc. lactis
DPC3147 (1%, v/v) was grown at 30 8C for 16 h in
M17 broth (DIFCO, Becton, Dickinson and Company,
Maryland, USA), containing 0.5% lactose (w/v) (LM17).
In Trial 1, 2 ml of this overnight culture was mixed with
3 ml of sterile Water for Injection B.P. (Antigen
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Pharmaceuticals Ltd., Roscrea, Ireland) and the 5 ml di-
luted culture/water mix was used as the treatment.
In Trial 2, in an effort to develop a commercially viable
live culture product, a washed cell suspension was in-
fused. Treatments were prepared in this trial by incubating
Lc. lactis DPC3147 for 16 h at 30 8C in LM17. The cells
were subsequently harvested by centrifugation at 3500 g
for 15 min and the supernatant discarded. The cell pellet
was then washed with sterile water, centrifuged again and
resuspended in sterile water. This suspension was divided
into 5-ml volumes and frozen at –80 8C. The frozen cul-
ture was then freeze dried in a Modulyo 4K Freeze drier
(Edwards, Sussex, UK). Before treatment, the freeze-dried
cell pellet was resuspended in 5 ml of sterile Water for
Injection B.P. (Antigen Pharmaceuticals Ltd., Roscrea,
Ireland). The resuspended live culture was then used as a
single treatment. This suspension contained approximately
9.1±0.5 log10 cfu/ml (colony forming units, average of 12
different counts) of live Lc. lactis DPC3147.
Treatment protocol
To compare the efficacy of treatment with lactococci v.
antibiotics, two trials were conducted, involving cows
with chronic subclinical or newly acquired clinical mas-
titis. Infected quarters in each trial were treated with live
culture or with antibiotics. As it is unethical to withhold
treatment from animals that are known to be infected,
untreated controls could not be used in the experiments.
In both trials, treatments were infused in an aseptic
manner after milking. For the infusion of the cultures, a
syringe with a blunted smoothed tip was used to prevent
injury to the teat. In Trial 1, the culture and water mixture
was infused after the morning milking on day 1 and day 2
of the trial, with a 24-h interval between treatments. The
antibiotic control treatment was administered at 12-h in-
tervals as per the manufacturer’s instructions, with admin-
istration following the morning and evening milkings
on day 1 and following the morning milking on day 2. As
Staph. aureus is one of the major causes of subclinical
mastitis in Ireland and >80% of Staph. aureus isolates
from Irish dairy herds exhibit a significant level of re-
sistance towards penicillin G (Barrett, 2004), the control
treatment was a commercial intramammary antibiotic
formulation containing amoxycillin (200 mg), clavulanic
acid (50 mg) and prednisolone (10 mg) (Synulox, Pfizer
Animal Health, New York, USA). Milk for human con-
sumption was withheld for five milkings after the last
treatment as instructed by the manufacturer.
In Trial 2, the resuspended culture was infused on day
1, day 2 and day 3 with 24-h intervals between treatments.
To standardize treatment intervals for the two treatments
and to provide a broad-spectrum treatment for naturally
occurring clinical cases, the antibiotic treatment in this
trial was a commercial formulation containing 150 mg
penethamate hydriodide, 150 mg dihydrostreptomycin
(as sulphate), 50 mg framycetin sulphate and 5 mg
prednisolone (Leo Yellow, Leo Laboratories Limited,
Ireland). This product was infused at 24-h intervals on day
1, day 2 and day 3 as recommended by the manufacturer.
Milk from cows treated with the antibiotic was withheld
from the bulk supply for seven milkings after the last
treatment.
Milk sampling protocol
Milk samples in both trials were taken prior to treatment
and on day 12 and day 14 after treatment in Trial 1 and
Trial 2, respectively, to monitor the progress of the infused
quarter. Before sample collection, teats were cleaned by
washing with water and then dried with service-paper to-
wels. Immediately before sampling, teats were disinfected
with cotton wool swabs containing methylated spirits
(Blackhall Pharmaceutical Distributors Ltd., Swords, Co.
Dublin, Ireland). Samples (20–25 ml) were collected in
single-use sterile plastic containers. In Trial 1, as the trea-
ted quarters had chronic subclinical infections, SCC was
measured and used as an indication of disease. In Trial 2,
the California Mastitis Test (CMT) and the presence of clots
were used as subjective measures of SCC as described
previously (Crispie et al. 2005). A clinical response in
Trial 2 was defined as a day 14 post-treatment sample that
showed no visible clots or flakes, whose udder condition
appeared normal and that had SCC <9r106 cells/ml. The
presence or absence of pathogens was not taken into ac-
count when classifying clinical response.
Microbiological assessment and bacterial enumeration
Milks obtained from animals in the studies were analysed
microbiologically following recommendations of the
International Dairy Federation (1981). In brief, 10 ml of
each milk sample was surface plated on aesculin blood
agar (ABA). ABA was prepared from Blood Agar Base
No. 2 (Merck, Darmstadt, Germany), containing 0.1%
aesculin (w/v) (Sigma-Aldrich Ireland Ltd., Dublin,
Ireland) and 5–8% (v/v) whole calf-blood. Plates were in-
cubated overnight at 37 8C and bacteria were identified on
colony appearance, growth characteristics, morphology
and on type of haemolysis. For analysis of the bacterial
counts in Trial 1, arbitrary values were assigned to
staphylococcal counts in a manner similar to that outlined
by Zadoks et al. 2003.
Bacteriological eliminations in Trials 1 and 2 were de-
fined as the absence of the infecting bacteria in the
last sample post-infusion (day 12 and day 14 respectively).
In Trial 2, a bacteriological response was defined as a
day 14 post-treatment sample with SCC <1r106 cells/ml
and a pathogen count <500 cfu/ml. These values were in
a similar range to those used by Corlett et al. (1984) as a
threshold to define infected from non-infected quarters in
a study examining the effect of an intramammary device in
the control of mastitis.
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In cases where the same bacterial species isolated on
day 1 persisted throughout the experimental period in Trial
2, bacteria were purified after isolation and cultures were
stored in 80% glycerol at –20 8C. These isolates were later
subjected to 16s rRNA sequencing which was carried out
essentially as described by Simpson et al. (2002).
Statistical analysis and data processing
The overall number of cases showing a clinical or a
bacteriological response in Trial 2 was analysed using
Chi-Square analysis, allowing a comparison of cases
treated with the culture with cases in the control group
(intramammary antibiotic treatment). Fisher’s Exact
Probability Test was used for a comparison of clinical re-
sponses and bacteriological responses in the subgroups.
SCC was available in precise counts up to 9.99r106
cells/ml milk. Beyond this value, the somatic cells in a
sample were estimated using CMT score and clinical ap-
pearance.
Results
Given that we had previously demonstrated that the bac-
teriocin lacticin 3147 was effective in preventing both
staphylococcal and streptococcal mastitis (Ryan et al.
1998, 1999a; Twomey et al. 2000; Crispie et al. 2005) we
decided to test the efficacy of the producing culture for
treatment of the disease. It is important to emphasize that
in both these trials high numbers of lactococci could be
found in most quarters at the first milking post infusion
but the culture did not survive for longer than 14 d in any
of the treated udder quarters (data not shown).
Trial 1
In Trial 1, 22 chronic subclinical infections in 12 cows
were treated with live culture or an intramammary anti-
biotic and the effects on pathogen survival and on SCC
were observed. Most cows had two infected quarters and
in these animals, one infected quarter was treated with Lc.
lactis and the other with antibiotic. All cows were in
late lactation, 6 cows were in 1st or 2nd lactation and 6
were in greater than 3rd lactation. Overall, pathogens
were eliminated from four quarters treated with Lc. lactis
and from three Staph. aureus infected quarters treated
with amoxycillin/clavulanic acid (Table 1). SCC levels re-
mained relatively unchanged in both groups.
Bacteriology
Of the 22 chronic subclinical infections, most were
caused by Staph. aureus. The level of pathogen found and
the SCC of milk samples on days 0 and 12 are shown
(Table 1). Overall, on day 12, 7 of 11 quarters treated
with Lc. lactis and 5 of 11 treated with antibiotics were
pathogen-free. On day 12, 3 of the 6 quarters treated with
Lc. lactis DPC3147 that had originally been infected with
Staph. aureus were no longer shedding staphylococci or
any other pathogen. One quarter in the culture treated
group that had been chronically infected with Strepto-
coccus uberis also showed no bacterial growth on day 12.
In the group treated with antibiotics, 3 of the 8 quarters
originally infected with Staph. aureus were pathogen-free
on day 12. In each treatment group, culture and amoxy-
cillin/clavulanic acid, one case that had no pathogen
isolation on day 0 showed staphylococcal growth at the
last sampling (Table 1).
SCC response
Overall, in Trial 1, SCC remained relatively unchanged
regardless of treatment. On the final day of sampling
(day 12), one quarter in each treatment group had an
SCC<3r105 cells/ml (Table 1). Average log SCC pre- and
post-treatment in the lactococci-treated group were
6.33±0.41 (day 0) and 6.27±0.43 cells/ml (day 12) and
average log SCC pre- and post-treatment in the antibiotic
Table 1. Bacteriological and SCC response to intramammary
infusion of Lc. lactis DPC3147 or an intramammary antibiotic
containing amoxycillin/clavulanic acid in chronic subclinical
infections in Trial 1
Case No.†
Bacteriology‡ (SCCr10– 3) cells/ml
Day 0 Day 12 Day 0 Day 12
1 0 0 4759 6138
2 + 0 5227 2399
3 ++· 0 592 1358
4 0 0 2388 2697
5 ++ ++ 3690 3939
6 ++ 0 3638 138
7 + 0 5601 2604
8 0 ++ 390 1124
9 ++ + 2892 2998
10 +++ +++ 2057 2388
11 0 0 661 1568
12 + + 7659 5318
13 ++ 0 761 406
14 ++ 0 1735 1141
15 +++ ++ 2160 2862
16 + + 2999 1539
17 0 0 428 854
18 0 0 1602 206
19 + 0 3371 6052
20 0 + 3030 2730
21 +++ ++ 1653 1885
22 + ++ 6684 4281
† Cases 1–11 were treated with Lc. lactis and cases 12–22 were treated
with the antibiotic control treatment
‡ Bacteria were enumerated and scored according to the following:
0=Absence of pathogens + = <40 cfu/10 ml, ++ =40–400 cfu/ml and
+++ =>400 cfu/ml
· Str. uberis infection
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treated group were 6.34±0.37 (day 0) and 6.22±0.46
cells/ml (day 12).
Trial 2
Fifty cases of clinical mastitis in 48 cows were selected
for Trial 2, with two cows presenting clinical mastitis in
two different quarters at different time points. The parity,
lactation status and previous mastitis history of the cows
enrolled in Trial 2 are shown in Table 2. To mimic normal
farming conditions, where farmers treat clinical cases
‘blindly’ as they appear throughout the lactation period,
cases were enrolled and randomized at the time of detec-
tion, immediately prior to treatment. Using this technique,
the treatment groups could not be stratified either on
parity, lactation status or mastitis history. The effect of
the treatments on bacteriology and disease symptoms was
assessed in the 50 cases as described in Materials and
Methods.
Bacteriology
Table 3 shows the pathogen types recovered from milk
samples taken on day 0 and day 14 for both culture and
antibiotic treated groups, respectively. Pathogens were
present in 35 of the day 0 samples, culture (n=17) and
antibiotic (n=18). Overall bacteriological elimination rates
were 61% (11/18) and 47% (8/17) for antibiotic and live
culture treatments respectively (Table 3).
Eighteen of the 35 pathogen positive cases on day 0
still showed growth of pathogens in the live culture (n=11)
and antibiotic treated groups (n=7) on day 14. Based on
colony morphology and haemolysis as well as 16s rRNA
sequencing (data not shown), it was concluded that in all
but two cases, the pathogen isolated from the final sample
was the same as the pathogen isolated on day 0, indicating
a persisting infection or re-infection with the same patho-
gen. The two cases where a new infection occurred were
both in quarters treated with the culture. In one of these
cases, Streptococcus dysgalactiae was isolated on day 0
and a non-haemolytic staphylococcus was isolated on day
14. In the second case, a mixture of Streptococcus uberis
and yeasts was isolated on day 0 and Staph. aureus was
isolated on day 14. These two cases were therefore classi-
fied as showing bacteriological elimination, as the original
infecting organism was no longer present (Table 3).
The treatment groups were also divided on the basis of
severity of mastitis in addition to showing pathogen growth
on day 0, i.e. culture mild (n=7), culture severe (n=10),
antibiotic mild (n=8) and antibiotic severe (n=10)
subgroups. In the group treated with the culture, two of
the mild (2/7) and four of the severe cases (4/10) had no
detectable pathogen on day 14. In the antibiotic-treated
group, 4 of the 8 mild pathogen-positive cases and 7 of the
10 severe cases were negative on day 14.
Overall, 16 of the 50 treated quarters (32%) showed a
bacteriological response, i.e. had a day 14 post-treatment
sample with an SCC <1r106 cells/ml and a pathogen
count of <500 cfu/ml. In the group treated with Lc. lactis,
this was achieved in 7 of 25 quarters (28%), whereas 9
cases responded to the antibiotic treatment (38%) (Table
3). The difference in overall bacteriological response rates
between the Lc. lactis treated group and the antibiotic
treated group was not statistically significant (P=0.5443).
Treatment groups were subdivided according to the se-
verity of mastitis on day 0 (mild and severe). In the mild
clinical group, 4 of 13 cases treated with Lc. lactis and 4
of 12 cases treated with the antibiotic showed a bacterio-
logical response. In the severe cases, 3 of 12 quarters
treated with the culture and 5 of 13 quarters treated
with the antibiotic showed a bacteriological response
(Table 3).
In 15 of the day 0 samples, no pathogen growth was
observed following overnight incubation at 37 8C. Of
these, 10 remained negative on day 14: 5 had been treated
with antibiotic (3 in the mild group, 2 in the severe group)
and a further 5 had been treated with Lc. lactis (4 in the
mild group and 1 in the severe group). Interestingly, 5 of
the 15 day 0 pathogen negative samples showed bacterial
growth on day 14. Str. uberis (n=2) and Str. dysgalactiae
(n=1) were isolated from three of these cases treated with
the culture. Both Str. uberis infected quarters were asso-
ciated with mild clinical symptoms, whereas the Str. dys-
galactiae infection was classified as severe. Staph. aureus
was isolated from one mild and one severe mastitis case in
the antibiotic treated group on day 14.
Clinical response
Fifty quarters were diagnosed with mastitis and selected
for the trial. There were 13 and 12 out of the 25 mild cases
Table 2. Cow parity, days in milk (DIM) and previous history of
mastitis at the time of enrolment in Trial 2
Number of cases
treated with
live culture
Number of cases
treated with
antibiotic control
treatment
Lactation No. at
enrolment
Lactation1 6 11
Lactation2 3 3
Lactation3 4 2
Lactation>3 12 9
Total 25 25
DIM at enrolment
Early lactation (f90 d) 16 18
Mid lactation(90–180 d) 8 5
Late lactation (o180 d) 1 2
Total 25 25
Previous mastitis history
of enrolled quarters
Total 6 3
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in culture or antibiotic treated groups, respectively.
Furthermore, 12 cases treated with the culture and 13
cases treated with the antibiotic were diagnosed as severe
on day 0. An illustration of udder secretions from mild and
severe cases on day 0 is shown in Fig. 1. Overall, 15 of the
25 cases treated with the culture and 18 of the 25 cases
treated with the antibiotic showed a clinical response at
day 14. This difference was not significant (P=0.5443).
Nine of the 13 mild clinical quarters treated with Lc. lactis
and 8 of 12 mild cases treated with the antibiotic showed
a clinical response at the final sampling. In the severe
cases, 6 of 12 cases treated with the culture responded
clinically on day 14, compared with 10 of 13 cases treated
with the antibiotic (Fig. 1).
Discussion
The aim of the two studies reported here was to evaluate
the effectiveness and safety of a live culture of Lc. lactis
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Fig. 1. Trial 2: Clinical responses on day 14 in culture and antibiotic treated quarters with photographs of a milk sample on day 0
from one mild clinical and one severe clinical case.
Table 3. Bacteriological elimination and bacteriological responses in clinical quarters treated with live culture (Top) or antibiotics
(Bottom) in Trial 2
Pathogen type
Day 0 (no.
of cases)
Day 14 (no. of cases
showing bacterial elimination)
Day 14 (no. of cases showing
bacteriological responses)
No pathogen isolated† 8 5 4
Staph. aureus (haemolytic) 7 3 2
Staph. aureus (non-haemolytic) 1‡ 1 0
Str. dysgalactiae 5 2· 1
Str. uberis 1 0 0
Other streptococci 1 1 0
Escherichia coli (non-haemolytic) 1 0 0
Others (Yeasts, Arcanobacterium
pyogenes)
1¶ 1· 0
Total no. of cases 25 13 7
No pathogen isolated †† 7 5 5
Staph. aureus (haemolytic) 8 4 1
Str. dysgalactiae 5 2 1
Str. uberis 3 3 1
Escherichia coli (non-haemolytic) 1‡ 1 0
Others (Yeasts, Arcanobacterium
pyogenes)
1 1 1
Total no. of cases 25 16 9
† Cases treated with live culture
‡ quarter dried off before day 14, secretions plated
·one quarter showed elimination of the pathogen isolated on day 0 and showed a different pathogen on day 14, indicating a new infection with a different
organism had occurred
¶ mixed infection with Str. uberis and yeasts
††Cases treated with antibiotic
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DPC3147 for the treatment of clinical and chronic sub-
clinical cases of naturally occurring mastitis.
In Trial 1, the efficiacy of the live culture treatment was
examined in cows with chronic subclinical Staph. aureus
mastitis. Although some studies consider treating chronic
subclinical cases during lactation to be beneficial
(Swinkels et al. 2005) it is generally regarded as contro-
versial and most farmers do not attempt it. Usually, best
treatment results for chronic subclinical mastitis are
achieved when affected quarters are treated during the dry
period. If dry cow therapy fails, it has been suggested that
the best option is to cull the animals (Sandgren et al.
2008). The mode of action of the culture treatment is
believed to be very different from conventional antibiotic
treatments (Crispie et al. 2008), however, and for this
reason, it was decided initially to examine the effect of the
treatment on subclinical mastitis cases in lactating cows
from both safety and efficacy perspectives. Of the cases
initially shedding Staph. aureus, no staphylococci could
be isolated at the last sampling in 4 of 7 infected quarters
(57%) treated with the culture and in 3 of 8 infected
quarters (38%) treated with antibiotics. Previously, bac-
teriological cure rates for Staph. aureus-induced sub-
clinical mastitis was found to be 43% for amoxycillin and
cephapirin (Wilson et al. 1999) and thus the bacteriologi-
cal elimination rate appeared to be similar to cure rates of
some antibiotics, in this small preliminary trial. Cured
quarters, however, are usually defined as not only being
pathogen free, but also having an SCC <2r105 cfu/ml. As
SCC was not considered in our definition of bacterial
elimination, a direct comparison cannot be made, but our
results imply similar trends for both treatments. If the
similar results found for live culture and antibiotic treat-
ment were confirmed in a larger study, the treatment of
subclinical mastitis with the culture during lactation could
be considered beneficial, as no cost through milk with-
drawal would arise. In cases of treatment success, the
major financial loss due to culling would also be pre-
vented.
The results of Trial 2 showed that the difference be-
tween the overall bacteriological response rate and the
clinical response rate for the culture treatment v. the anti-
biotic treatment was not statistically significant (P=0.5443
and P=0.5443 for bacteriological responses and clinical
responses, respectively). In terms of bacterial elimination,
11 of 18 (61%) and 6 of 17 (35%) cases treated
with antibiotic and culture treatment, respectively, were
pathogen free at the end of Trial 2. At first glance, this
would suggest that the antibiotic treatment seemed to
compare favourably with the culture treatment. However,
a further two cases treated with the live culture, although
not pathogen free on day 14 had in fact eliminated the
original infecting organism, bringing the elimination rate
for this treatment to 47% (8/17). Although the numbers are
relatively small and again SCC was not taken into con-
sideration, indications are that the live culture may there-
fore be as effective as the antibiotic treatment.
Bacteriological elimination of Staph. aureus infections
in Trial 2 was achieved for 3 of 7 and 4 of 8 cases in the
culture and antibiotic group, respectively. Owens et al.
(1997) previously found that using a combination of peni-
cillin and novobiocin, bacteriological cure rates for clini-
cal mastitis caused by Staph. aureus could be as high as
70% if treatment was initiated at the early stage of infec-
tion (<28 d) and could be as low as 35% for animals with
chronic infections. These figures compare favourably with
the bacteriological elimination rates achieved with Lc.
lactis and the antibiotic control used in Trial 2, especially
if we consider that some of the Staph. aureus treated cases
may have been chronic. It is well known that Staph. aur-
eus causes microabscesses inside the mammary gland and
therefore the pathogens may be protected from antibiotic
access and shed in a cyclical manner. Consecutive sam-
pling is sometimes recommended for a more accurate di-
agnosis of the mastitis event (Sears et al. 1990). Since this
level of sampling was not carried out in Trial 2, it is poss-
ible that some of the 15 day-0 pathogen-negative samples
may well have been associated with chronic Staph. aureus
infections and the intermittent shedding pattern of these
pathogens.
Other pathogens isolated in the trials were Str. uberis
(1 and 4 cases in Trials 1 and 2, respectively) and
Str. dysgalactiae (10 in Trial 2). Bacteriological cure rates
for both streptococcal strains when treated with penicillin
alone were reported to be 60–90% (Sandholm et al. 1995)
and when treated with a combination of penicillin and
novobiocin were 90% and 91%, respectively (Owens
et al. 1997). Three out of five Str. dysgalactiae related
cases persisted in each treatment group in Trial 2, there-
fore elimination rates for both treatments were lower than
the published cure rates. The three cases of Str. uberis
mastitis treated with the antibiotic in Trial 2 showed no
pathogen growth on day 14. The elimination rate for this
pathogen by antibiotics in Trial 2 is therefore similar to the
published cure rates. In contrast, the only Str. uberis case
in Trial 2 treated with the culture persisted on day 14.
Str. uberis is a mastitis pathogen that can internalize into
epithelial cells for up to 120 h without affecting the
viability of the host cell (Almeida et al. 2005). Trials by
Crispie et al. (accompanying paper) have shown that
Lc. lactis DPC3147 causes an immediate, short-lived effect
on the immune system and therefore a longer interval
between doses might be more effective in treating slow
progressing Str. uberis type infections.
As it is unethical to withhold treatment from animals
that are known to be infected, untreated controls could
not be used in the experiments and thus the results of the
experiments must be considered in conjunction with
spontaneous recovery. Most spontaneous recoveries occur
in quarters with mild or recent infections and only rarely in
the case of well-established or chronic infections such as
those encountered in Trial 1. However, some cows re-
cover from clinical mastitis spontaneously: the rate of
spontaneous recovery of untreated mastitis caused by
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Staph. aureus is approximately 15–20% and in untreated
cases of streptococcal mastitis is approximately 20–25%
(Sandholm et al. 1995; Nickerson et al. 1999). The small
numbers of cases in these studies make comparison diffi-
cult but it appears that the rate of elimination of pathogens
observed is higher than that expected from spontaneous
recovery. Moreover, the rates were comparable across
treatment, i.e the live culture appeared to be as effective as
the antibiotic treatments. Factors such as age, and previous
history of mastitis can also effect recoveries as it has been
shown that mastitis in older cows, or in cows with a pre-
vious history of mastitis, is more difficult to treat than in
younger animals (Sandgren et al. 2008). In Trial 2, cases of
clinical mastitis were randomly assigned to culture or
antibiotic treatment as they arose, without knowledge of
factors such as parity, days in milk at the time of enrolment
and previous mastitis history. When these data were ex-
amined retrospectively, it was observed that overall,
cows in the culture-treated group were older than in the
antibiotic group. Additionally, twice as many cases in the
culture group had a previous history of mastitis or high
SCC, compared with the antibiotic group. In a larger trial
involving more cases, the culture treatment might there-
fore show better results than in the present study.
Like many other intramammary antibiotics, the
formulations used in this study contained a mixture of
antibiotics and the anti-inflammatory component
prednisolone. Prednisolone belongs to a group of sub-
stances called steroidal anti-inflammatories and mainly
aids the reduction of swelling and related pain in in-
tramammary treatments (Lees, 1991). Indeed, the better
accessibility of the antibiotics to the pathogens due to
lower inflammation possibly led to a quicker recovery.
This may be an explanation for the numerical differences
encountered in response rates of the severe cases for both
treatments in Trial 2. In contrast, treatment with Lc. lactis
DPC3147 seems to be associated with transient elevated
SCC. This effect on the immune system might aid in the
recovery of an inflamed quarter, especially as the mam-
mary gland immune response in Staph. aureus related
mastitis is evidently suppressed and down-regulated
(Alluwaimi, 2004). In support of this, recent results from
our laboratory have confirmed that the infusion of live
cultures into quarters of low-cell-count animals is asso-
ciated with a rapid influx of neutrophils in the first 2 d post
infusion (Crispie et al. 2008). It is believed that this influx
of PMN may enhance the intramammary immune re-
sponse. The influx of PMN was also associated with a
short-lived rise in SCC; however SCC rapidly decreased to
pre-treatment levels, probably reflecting the inability of
Lc. lactis to establish in the treated quarters, and no lasting
adverse effects from the treatment were observed in any of
the animals in any of the trials, demonstrating the safety of
the treatment.
Alternative treatments such as the live culture treatment
may have an application in the growing organic sector
where the use of antibiotic treatments is limited or even
prohibited. The live culture treatment also has potential to
reduce the costs associated with the disease, as is esti-
mated that approximately 5.7% of the cost of mastitis is
due to discarding of milk containing antibiotic residues
(Costello, 2004). Lc. lactis DPC3147 is used in food pro-
duction (Ryan et al. 1998) and it is likely that as a result,
milk from quarters treated with this organism would
only have to be withheld until normal milk character is
restored. Additionally, the ongoing discovery of more
multiple resistant strains of pathogens, which is well
documented through the risk posed by methicillin and
vancomycin resistant Staph. aureus (MRSA and VRSA),
will require a reduction in the use of antibiotics in every
sector in the future. It would now be interesting to com-
pare antibiotic therapies with this more natural approach
in the larger field trials that would be required for regu-
latory approval.
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